BACKGROUND: Little is known about the long-term outcomes of African American living kidney donors (AALKDs). We undertook this study to describe renal outcomes of AALKDs several years after donation. METHODS: We invited 107 AALKDs to come for follow-up health evaluation. RESULTS: Thirty-nine subjects (36.4%) completed evaluation at a mean of 7.1+/-1.6 (range, 3.9-10.2) years postdonation. The mean estimated glomerular filtration rate using the abbreviated Modification of Diet in Renal Disease equation [eGFR(MDRD)] at follow-up was 72.1+/-16.3 (range, 42-106) mL/min/1.73 m2, and 18% of subjects had an eGFR(MDRD) of 30 to 59. The mean absolute and relative decrease in eGFR(MDRD) from the time of donation to follow-up was 30.5+/-16.4 mL/min/1.73 m2 and 28.8%, respectively. Subjects whose body mass index was more than or equal to 35 kg/m2 (n=8) were found to have a greater decrement in e(MDRD) than those with body mass index less than 35 kg/m2 (40.1+/-7.3 and 28.3+/-17.1 mL/min/1.73 m2, respectively; P=0.009). Sixteen (41%) were hypertensive at follow-up, as defined as treatment with antihypertensive medications (n=8) or average blood pressure of more than or equal to 140 systolic or 90 mm Hg diastolic (n=10, of whom two were on antihypertensive medications). One subject had macroalbuminuria (>300 microg/mg creatinine), and six (15.4%) had microalbuminuria (30-300 microg/mg creatinine). CONCLUSIONS: AALKDs experience a substantial incidence of hypertension and a modest drop in eGFR(MDRD) postdonation, and obesity may increase the magnitude of renal decline. Further study is urgently needed to determine the long-term risks of AALKDs.
BACKGROUND: Little is known about the long-term outcomes of African American living kidney donors (AALKDs). We undertook this study to describe renal outcomes of AALKDs several years after donation. METHODS: We invited 107 AALKDs to come for follow-up health evaluation. RESULTS: Thirty-nine subjects (36.4%) completed evaluation at a mean of 7.1+/-1.6 (range, 3.9-10.2) years postdonation. The mean estimated glomerular filtration rate using the abbreviated Modification of Diet in Renal Disease equation [eGFR(MDRD)] at follow-up was 72.1+/-16.3 (range, 42-106) mL/min/1.73 m2, and 18% of subjects had an eGFR(MDRD) of 30 to 59. The mean absolute and relative decrease in eGFR(MDRD) from the time of donation to follow-up was 30.5+/-16.4 mL/min/1.73 m2 and 28.8%, respectively. Subjects whose body mass index was more than or equal to 35 kg/m2 (n=8) were found to have a greater decrement in e(MDRD) than those with body mass index less than 35 kg/m2 (40.1+/-7.3 and 28.3+/-17.1 mL/min/1.73 m2, respectively; P=0.009). Sixteen (41%) were hypertensive at follow-up, as defined as treatment with antihypertensive medications (n=8) or average blood pressure of more than or equal to 140 systolic or 90 mm Hg diastolic (n=10, of whom two were on antihypertensive medications). One subject had macroalbuminuria (>300 microg/mg creatinine), and six (15.4%) had microalbuminuria (30-300 microg/mg creatinine). CONCLUSIONS: AALKDs experience a substantial incidence of hypertension and a modest drop in eGFR(MDRD) postdonation, and obesity may increase the magnitude of renal decline. Further study is urgently needed to determine the long-term risks of AALKDs.
Authors: Michelle E Tarver-Carr; Neil R Powe; Mark S Eberhardt; Thomas A LaVeist; Raynard S Kington; Josef Coresh; Frederick L Brancati Journal: J Am Soc Nephrol Date: 2002-09 Impact factor: 10.121
Authors: D A Laskow; P Jones; M H Deierhoi; E V Dubovsky; B A Julian; W H Barber; A G Diethelm; J J Curtis Journal: Transplant Proc Date: 1991-02 Impact factor: 1.066
Authors: D A Goldfarb; S F Matin; W E Braun; M J Schreiber; B Mastroianni; D Papajcik; H A Rolin; S Flechner; M Goormastic; A C Novick Journal: J Urol Date: 2001-12 Impact factor: 7.450
Authors: Hassan N Ibrahim; Robert Foley; LiPing Tan; Tyson Rogers; Robert F Bailey; Hongfei Guo; Cynthia R Gross; Arthur J Matas Journal: N Engl J Med Date: 2009-01-29 Impact factor: 91.245
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: C R Gross; E E Messersmith; B A Hong; S G Jowsey; C Jacobs; B W Gillespie; S J Taler; A J Matas; A Leichtman; R M Merion; H N Ibrahim Journal: Am J Transplant Date: 2013-09-06 Impact factor: 8.086
Authors: Mona D Doshi; Mariella Ortigosa-Goggins; Amit X Garg; Lihua Li; Emilio D Poggio; Cheryl A Winkler; Jeffrey B Kopp Journal: J Am Soc Nephrol Date: 2018-01-16 Impact factor: 10.121
Authors: Krista L Lentine; Mark A Schnitzler; Huiling Xiao; Georges Saab; Paolo R Salvalaggio; David Axelrod; Connie L Davis; Kevin C Abbott; Daniel C Brennan Journal: N Engl J Med Date: 2010-08-19 Impact factor: 91.245
Authors: Tanjala S Purnell; Neil R Powe; Misty U Troll; Nae-Yuh Wang; Carlton Haywood; Thomas A LaVeist; L Ebony Boulware Journal: Clin Transplant Date: 2013-08-01 Impact factor: 2.863
Authors: Milos N Budisavljevic; Paul J Nietert; Yusheng Zhai; Mary J Dooley; P R Rajagopalan Journal: Clin J Am Soc Nephrol Date: 2011-05-05 Impact factor: 8.237
Authors: Harini A Chakkera; Yu-Hui H Chang; Leslie F Thomas; Ramesh T Avula; Hatem Amer; Lilach O Lerman; Aleksandar Denic; Andrew D Rule Journal: Transplant Direct Date: 2015-02-01
Authors: Krista L Lentine; Mark A Schnitzler; Huiling Xiao; David Axelrod; Amit X Garg; Janet E Tuttle-Newhall; Daniel C Brennan; Dorry L Segev Journal: Transplantation Date: 2014-02-15 Impact factor: 4.939